1	
2	
3	
4	
5	
6	
7	Individual Participant Data Network Meta-analysis of psychosocial interventions for survivors
8	of intimate partner violence: Study protocol
9	Authors: Christina Palantza <u>christina.palantza@bristol.ac.uk</u> <sup>1</sup> , Karen Morgan
10	<u>karen.morgan@bristol.ac.uk</u> <sup>1</sup> , Nicky J. Welton <u>nicky.welton@bristol.ac.uk</u> <sup>1</sup> , Hannah M.
11	Micklitz <u>hannah.micklitz@psychologie.uni-freiburg.de</u> <sup>2</sup> , Lasse B. Sander
12	lasse.sander@mps.uni-freiburg.de <sup>2</sup> , Gene Feder <u>gene.feder@bristol.ac.uk</u> <sup>1</sup>
13	1. Bristol Medical School, Department of Population Health Sciences, University of Bristol,
14	Bristol, United Kingdom
15	2. Medical Psychology and Medical Sociology, Faculty of Medicine, University of Freiburg,
16	Freiburg, Germany
17	
18	

19	ABSTRACT
20	Many systematic reviews and meta-analyses have been conducted in the field of Intimate
21	Partner Violence (IPV) and the evidence shows small to moderate effect sizes in improving mental
22	health. However, there is considerable heterogeneity due to great variation in participants,
23	interventions and contexts. It is therefore important to establish which participant and intervention
24	characteristics affect the different psychosocial outcomes in different contexts. Individual Participant
25	Network Meta-analysis (IPDNMA) is a gold-standard method to estimate the effects with the highest
26	precision possible and estimate moderating effects, compare the effectiveness of the different
27	interventions and thus answer the question of which intervention is best-suited for whom. We will
28	conduct an IPDNMA of randomised controlled trials (RCTs) of psychosocial interventions for IPV
29	survivors aimed at improving mental health, well-being, risk-lowering and intervention acceptability
30	outcomes compared to any type of control (PROSPERO registration number: CRD42023488502). We
31	aim to establish a collaboration with the authors of the eligible RCT, to obtain and to harmonise the
32	Individual Participant Data of the trials, and conduct an one-stage IPDNMA will be conducted under a
33	Bayesian framework using the multinma package in R, after testing which characteristics of the
34	participants and interventions are effect modifiers. There are however inherent limitations of IPDMAs,
35	such as depending on data availability and missing nuancing through the harmonisation of variables.
36	We aim to address these possibly by creating pseudo-IPD and sensitivity analyses. This approach is
37	novel in the field and it can inform more efficient clinical and policy-related decision making.

# 38 Introduction

39	The term Intimate Partner Violence (IPV) covers all forms of aggression towards a current or
40	former intimate partner, including psychological, physical, sexual, or coercive controlling behaviours
41	(1). One of the most severely impacted aspects is the mental health of the survivors (2); in fact mental
42	disorders are more common among both men and women involved in IPV than in the general
43	population (3). The course of IPV is intertwined with the course of mental distress (4). IPV is a
44	worldwide public health issue (5), and it has highly adverse outcomes for victims/survivors,
45	perpetrators and children (6,7,8). IPV was further exacerbated during the COVID-19 pandemic (9).
46	This increase has been consistently associated with a generally well-established risk factor for IPV,
47	which is financial strain (10,11). Therefore, it is likely to continue rising during the current cost of
48	living crisis, which is affecting many regions around the world (12), and non-governmental
49	organisations working with survivors are already reporting the negative impact of the crisis (13).
50	There is thus a heightened necessity for efficient services that are targeted to meet individuals' needs
51	by utilising only the resources that are needed.
52	Despite the heightened need, psychosocial care for survivors appears inadequate both in terms
52	
53	of accessibility and quality (14). The psychosocial interventions tested in research settings show some
53 54	of accessibility and quality (14). The psychosocial interventions tested in research settings show some potential (15), but effect sizes are rather small (i.e. Standardised Mean Difference of -0.15 to -0.26) for
53 54 55	of accessibility and quality (14). The psychosocial interventions tested in research settings show some potential (15), but effect sizes are rather small (i.e. Standardised Mean Difference of -0.15 to -0.26) for major psychological outcomes such as depression, or inconsistent across reviews for safety and re-
53 54 55 56	of accessibility and quality (14). The psychosocial interventions tested in research settings show some potential (15), but effect sizes are rather small (i.e. Standardised Mean Difference of -0.15 to -0.26) for major psychological outcomes such as depression, or inconsistent across reviews for safety and re-victimisation, and both clinical and statistical heterogeneity of the intervention effects are high
53 54 55 56 57	of accessibility and quality (14). The psychosocial interventions tested in research settings show some potential (15), but effect sizes are rather small (i.e. Standardised Mean Difference of -0.15 to -0.26) for major psychological outcomes such as depression, or inconsistent across reviews for safety and revictimisation, and both clinical and statistical heterogeneity of the intervention effects are high (15,16). This could be attributed to heterogeneous populations (17). Moreover, the quality of the
53 54 55 56 57 58	of accessibility and quality (14). The psychosocial interventions tested in research settings show some potential (15), but effect sizes are rather small (i.e. Standardised Mean Difference of -0.15 to -0.26) for major psychological outcomes such as depression, or inconsistent across reviews for safety and re- victimisation, and both clinical and statistical heterogeneity of the intervention effects are high (15,16). This could be attributed to heterogeneous populations (17). Moreover, the quality of the evidence is questionable, as many studies do not use optimal design (18), and those that do have not
53 54 55 56 57 58 59	of accessibility and quality (14). The psychosocial interventions tested in research settings show some potential (15), but effect sizes are rather small (i.e. Standardised Mean Difference of -0.15 to -0.26) for major psychological outcomes such as depression, or inconsistent across reviews for safety and re-victimisation, and both clinical and statistical heterogeneity of the intervention effects are high (15,16). This could be attributed to heterogeneous populations (17). Moreover, the quality of the evidence is questionable, as many studies do not use optimal design (18), and those that do have not reported all necessary information sufficiently (16). In addition, many important aspects, such as long-
53 54 55 56 57 58 59 60	of accessibility and quality (14). The psychosocial interventions tested in research settings show some potential (15), but effect sizes are rather small (i.e. Standardised Mean Difference of -0.15 to -0.26) for major psychological outcomes such as depression, or inconsistent across reviews for safety and re- victimisation, and both clinical and statistical heterogeneity of the intervention effects are high (15,16). This could be attributed to heterogeneous populations (17). Moreover, the quality of the evidence is questionable, as many studies do not use optimal design (18), and those that do have not reported all necessary information sufficiently (16). In addition, many important aspects, such as long- term effects, harms, and differential effects for survivors with different characteristics from different
53 54 55 56 57 58 59 60 61	of accessibility and quality (14). The psychosocial interventions tested in research settings show some potential (15), but effect sizes are rather small (i.e. Standardised Mean Difference of -0.15 to -0.26) for major psychological outcomes such as depression, or inconsistent across reviews for safety and revictimisation, and both clinical and statistical heterogeneity of the intervention effects are high (15,16). This could be attributed to heterogeneous populations (17). Moreover, the quality of the evidence is questionable, as many studies do not use optimal design (18), and those that do have not reported all necessary information sufficiently (16). In addition, many important aspects, such as long-term effects, harms, and differential effects for survivors with different characteristics from different contexts remain unanswered, despite the indications towards considerable impact of these differences
53 54 55 56 57 58 59 60 61 62	of accessibility and quality (14). The psychosocial interventions tested in research settings show some potential (15), but effect sizes are rather small (i.e. Standardised Mean Difference of -0.15 to -0.26) for major psychological outcomes such as depression, or inconsistent across reviews for safety and re- victimisation, and both clinical and statistical heterogeneity of the intervention effects are high (15,16). This could be attributed to heterogeneous populations (17). Moreover, the quality of the evidence is questionable, as many studies do not use optimal design (18), and those that do have not reported all necessary information sufficiently (16). In addition, many important aspects, such as long- term effects, harms, and differential effects for survivors with different characteristics from different contexts remain unanswered, despite the indications towards considerable impact of these differences (16,18). This is particularly problematic, because the survivors are indeed quite diverse and come from
<ul> <li>52</li> <li>53</li> <li>54</li> <li>55</li> <li>56</li> <li>57</li> <li>58</li> <li>59</li> <li>60</li> <li>61</li> <li>62</li> <li>63</li> </ul>	of accessibility and quality (14). The psychosocial interventions tested in research settings show some potential (15), but effect sizes are rather small (i.e. Standardised Mean Difference of -0.15 to -0.26) for major psychological outcomes such as depression, or inconsistent across reviews for safety and re- victimisation, and both clinical and statistical heterogeneity of the intervention effects are high (15,16). This could be attributed to heterogeneous populations (17). Moreover, the quality of the evidence is questionable, as many studies do not use optimal design (18), and those that do have not reported all necessary information sufficiently (16). In addition, many important aspects, such as long- term effects, harms, and differential effects for survivors with different characteristics from different contexts remain unanswered, despite the indications towards considerable impact of these differences (16,18). This is particularly problematic, because the survivors are indeed quite diverse and come from different contexts (e.g. staying with the perpetrator, staying in a shelter, co-parenting with the

65 Micklitz and colleagues categorised the tested psychosocial interventions into three main 66 categories: psychological, advocacy-oriented and integrated (a combination of the two). Psychological 67 interventions are psychotherapeutic interventions that employ cognitive, behavioural or emotion-68 focused techniques, and are usually delivered by a therapist through talking. Advocacy interventions 69 could be summarised as advice on practical matters and continued support and counselling, enhanced 70 access to other resources such as shelters, and facilitated safety planning (17). A realist review of 71 advocacy interventions highlighted the critical impact of the nuances both among survivors and 72 contexts, and the importance of matching the intervention to the survivor's context and needs (17). 73 However, the hypotheses were not tested statistically, and there was considerable variation among 74 interventions, that was not examined quantitatively. The heterogeneity of interventions has not 75 allowed conclusions on the effectiveness to be drawn for large groups of survivors, such as mothers 76 (20) and also blurs the evidence on certain types of interventions (21). This might also explain the 77 contradictory evidence on effectiveness of web-based interventions (22,23). There are indications that 78 all types of interventions have effects up to an extent for some of the possible outcomes (24), but these 79 effects should be investigated in further detail. 80 A methodological approach that is well-suited for investigating such nuances in terms of 81 population and intervention, is Individual Participant Data meta-analysis (IPDMA). This form of

82 meta-analysis pools individual level data instead of the aggregate data from the existing studies, by

83 requesting the datasets with the raw data from each eligible study and combining them all into one

84 harmonised dataset (25). Meta-analyses of aggregate data are limited to the outcomes reported in

85 publications and rely on study-level moderators lacking statistical power and are vulnerable to

86 ecological bias (26). IPDMA overcomes these limitations by allowing outcomes and effect modifiers

to be comparable across studies, enabling testing and adjusting for various within and between study

88 moderators, both participant and intervention-related, to establish the effect sizes for different

89 interventions and survivors (26,27,28). Importantly IPDMA has increased statistical power compared

90 to the original studies by pooling effects. This way, the findings of (29) that participant and

91 counselling characteristics have differential impact will be further elucidated.

92	Given the limited resources of health systems (30) and the different interventions tested for
93	IPV (16), it is promising to compare the efficacy of different interventions, and identify the best-suited
94	intervention for an individual based on their characteristics and context. A method that compares
95	multiple different interventions and ranks their efficacy is Network Meta-analysis (NMA) (31). This is
96	achieved by forming a network of all the interventions that have been tested for an outcome and
97	integrating direct and indirect evidence from direct comparisons of interventions (i.e. compared in the
98	same trial) with indirect ones (i.e. two interventions have not been tested in the same trial, but they
99	were tested against the same control condition), thus allowing for estimation of relative effects of pairs
100	of interventions and hierarchical ranking (32). The key assumption is that all included studies do not
101	differ in terms of factors that could impact the relative effects (32). An issue can be
102	inconsistency/imprecision, which occurs when the direct and indirect evidence give contradictory
103	results, and the use of IPD can help with increasing precision and validity of the estimates (33).
104	Individual Patient Data Network Meta-analysis (IPDNMA), which combines IPDMA to explore
105	individual and study-level moderators, and NMA to compare multiple interventions, provides the tools
106	to compare different interventions for different populations (34).
107	Aim and research questions
108	We will conduct an IPDNMA, an aggregate data network meta-analysis (NMA), a
109	conventional meta-analysis, and an IPDMA of the overall efficacy of psychosocial interventions, to
110	provide reliable and robust estimates of interventions and to examine which psychosocial intervention
111	suits individual IPV survivors best to improve psychosocial and safety outcomes. More specifically
112	the following research questions will be answered:
113	1. What is the overall efficacy and acceptability of psychosocial interventions in mental health
114	and safety of IPV victims/survivors (conventional meta-analysis)?
115	2. What is the precise overall efficacy and acceptability of psychosocial interventions in

- 116 achieving clinically relevant improvement or deterioration in the mental health and safety of
- 117 IPV victims/survivors (IPDMA)?

118	3.	Which psychosocial intervention is comparatively the most effective and acceptable in
119		improving mental health and safety of IPV victims/survivors (NMA)?
120	4.	Which victim/survivor and intervention characteristics moderate the efficacy and acceptability
121		of psychosocial interventions in improving mental health and safety of IPV victims/survivors
122		(IPDMA)?
123	5.	Which victim/survivor and intervention characteristics moderate the comparative effectiveness
124		and acceptability of each different psychosocial intervention in improving mental health and
125		safety of IPV victims/survivors (IPDNMA)?

# **Materials and Methods**

### 127 Design

- 128 This study aims to provide more precise and less biased estimates of the clinically relevant
- 129 benefits and harms, as well as moderators to that, of each type of psychosocial intervention
- 130 comparatively by obtaining the IPD of the studies to enable exploration and adjustment of effect
- 131 modifiers. For these purposes, an IPDNMA will be conducted, and also a conventional meta-analysis,
- an aggregate data network meta-analysis, and an individual participant data meta-analysis, to compare
- the results and investigate the differences. The study is an update and extension of the systematic
- 134 review of Micklitz and colleagues.

### 135 **Protocol registration**

- 136 The study protocol has been preregistered on PROSPERO (CRD42023488502) and a project
- 137 has been created on the Open Science Framework
- 138 <u>https://osf.io/72uwe/?view\_only=1ba290a378514c3a929d7eac035bfd67</u>. The Preferred Reporting
- 139 Items for systematic reviews and meta-analyses (PRISMA) statements for systematic review protocols
- 140 (PRISMA-P) (35) are followed (see appendix).

### 141 Eligibility criteria

- 142 The eligibility criteria based on the PICO (Participants, Interventions, Comparators and
- 143 Outcomes) are listed in Table 1.

#### 144 Table 1. Eligibility criteria by PICO

Participants       Individuals or couples reporting either past or ongoing IPV at randomisation, but         studies solely on those involved in perpetration are excluded         Interventions       Psychosocial interventions aimed at IPV survivors using any mode of delivery at any
studies solely on those involved in perpetration are excluded         Interventions         Psychosocial interventions aimed at IPV survivors using any mode of delivery at any
Interventions         Psychosocial interventions aimed at IPV survivors using any mode of delivery at any
Interventions Psychosocial interventions aimed at IPV survivors using any mode of delivery at any
setting. Both psychotherapeutic and advocacy interventions are deemed as
psychosocial. Interventions aimed solely at perpetrators, primary prevention to
individuals who have not experienced IPV at baseline, non-psychological risk factors
such as sexual behaviour or financial situation, and physical safety (such as being in a
refuge/shelter and police interventions) are not included.
<b>Comparators</b> All comparators are eligible, including no intervention, waiting list, Treatment as
Usual (TAU), another active intervention, placebo or sham version of the
intervention. The interventions will be categorised and classified into nodes of the
network based on their description regardless of whether they were tested as control
or active condition in the original studies.
<b>Outcomes</b> Eligible outcomes are all outcomes related to mental health and well-being (e.g.
depression, quality of life).

145

Only randomised controlled trials (RCTs) are eligible for inclusion, including pilot RCTs and studies with few participants, as they will be merged with larger studies testing a similar intervention. All papers published in peer-reviewed journals are eligible, as well as protocols and trial registrations in case the authors already have data that they can provide. No language or publication date restrictions are applied.

## 151 Identification of studies-information sources

A search strategy with keywords and phrases such as "intimate partner violence" and "psychotherapy" will be used to search the Web of Science database from inception to late November 2023 (see appendix for full search string). This search strategy was used by Micklitz and colleagues, so an update of their search will be performed in the databases they searched (PsycINFO, Medline, Embase, and Cochrane Central). Clinical trial registries will be searched, and forward and backward search will be performed.

### 158 Study selection process

159 Two independent researchers will screen the titles and abstracts. All completed studies 160 included in the systematic review of Micklitz et al will be included. The authors of all the protocols 161 and trial registrations identified by Micklitz and colleagues will be contacted to find out whether data 162 are available, and if they agree to share their data, they will be offered co-authorship of the 163 publications derived from the study. If the studies or protocols included at this stage have been 164 published, the full text will be screened by the two independent researchers. In the case of trial 165 registrations, the complete registrations will be screened by the two independent researchers, or a 166 detailed description will be requested from the principal investigators of the studies. In case of 167 disagreement between the two researchers, a third, senior member of the team will be consulted. The 168 screening and inclusion of abstracts and full texts will be done using Rayyan (36).

### 169 **Ethical considerations**

Since this type of study is essentially a secondary analysis of existing data, it does not need to be ethically approved. However, the trialists of the eligible RCTs are responsible for the ethical re-use of the data they collected, so it is up to them to either consult their local Ethical Review Boards and possibly to submit this re-use for ethical approval, or to request us to sign a Data Sharing Agreement with them. The secure handling of this sensitive type of data is described in the following section "Data Management".

#### 176 **Data management**

177 A collaborative project will be created on the Research Data Storage Facility of the University 178 of Bristol, managed by GF and accessible to the rest of the authors. The data can be uploaded to that 179 space by the authors of the primary studies. This cloud is compliant with the General Data Protection 180 Regulation. In case the authors face unresolvable issues with this cloud, secure sharing links to a 181 private folder at the institutional OneDrive of CP will be generated. As soon as the data have been 182 uploaded, they will be saved directly in the RDSF and removed from OneDrive. The data will be 183 copied to the university-managed and password protected device of CP for analysis. Since the data are 184 sensitive, a Data Protection Impact Assessment will be performed.

### 185 Data extraction of study characteristics and aggregate data

186 The study characteristics to be extracted in a spreadsheet are: author, publication year, citation, 187 country, recruitment setting, trial setting, number of trial arms, number of follow-ups, timing of 188 follow-ups, timing of post-treatment, primary and secondary outcomes, type of randomisation, unit of 189 allocation, method of randomisation, sample size in total and in each arm, treatment and study 190 dropout, intention-to-treat or per-protocol analysis, age, gender, current frequency and/or severity of 191 IPV, past frequency and/or severity of IPV, specific target population, eligibility criteria, description 192 of intervention, theoretical orientation, delivery mode, type of therapists/facilitators, number and 193 duration of sessions, frequency of sessions, description of control. The characteristics and aggregate 194 data extracted by Micklitz et al (16) will be used.

#### **Data collection**

The corresponding authors of eligible studies will be emailed and invited to share the individual-level data of their study. The most recent email address of the author will be sought. If necessary, a reminder will be sent after three weeks and six weeks. If unreachable, the same process will be followed for the senior author of the study. If no valid email address of neither the corresponding nor the senior author can be found, social networking websites such as ResearchGate and LinkedIn will be used to reach the authors, and the same number of reminders will be sent if necessary. The IPD will be deemed unavailable if no response is received after three weeks of the

second reminder to the senior author (12 weeks in total). After authors have accepted to share the IPD,

there is no specific time limit to send the data.

### 205 Data items

- 206 It is expected that not all eligible studies have collected data on all possible moderating
- 207 characteristics, such as income level, and in such a multifaceted issue, there can be various potentially
- 208 impactful variables. Therefore, the complete datasets will be requested including baseline and all
- available follow-ups, with an exception for variables that could lead to the identification of a
- 210 participant and violate anonymity.
- 211 Data harmonisation

212		A standard coding of the characteristics of participants will be established based on the	
213	operati	onalisation used by the majority of the studies and the data of each individual study will be	
214	recode	d accordingly. We currently propose the operationalisation below, but the final one will depend	
215	on the	data. If a study has not collected any data on some of the listed demographic or socio-economic	
216	characteristics, this will be taken into account in the quality assessment.		
217	1.	Biological sex: female/intersex	
218	2.	Gender identity: cisgender/transgender/gender non-conforming	
219	3.	Sexual orientation: heterosexual/homosexual/bisexual/other	
220	4.	Age at baseline: continuous variable	
221	5.	Relationship status: being in a relationship/not being in a relationship/not sure	
222	6.	Cohabitation status: cohabiting with partner/non-cohabiting with partner	
223	7.	Parenthood: parent living with children/parent having some contact with their children/ parent	
224		having no contact with their children/non-parent	
225	8.	Education: Uneducated / Primary education/ Secondary education/ Tertiary education/Other	
226	9.	Employment status: student/employed/unemployed seeking employment/unemployed not	
227		seeking/retired or disability	

- 228 10. Income level: OECD (Organisation for Economic Co-operation and Development) quintiles
- 11. Ethnicity: categorical variable with the respective ethnicities in the respective country/trial
- 230 12. Presence of psychiatric/developmental disorder
- 231 13. Presence of history of abuse in the family
- 232 14. Presence of substance dependence
- 233 The data from different validated scales will be divided by the standard deviation. If a study uses more
- than one scale for the same outcome, these scales will be combined in a sort of "within-study-
- synthesis". If any scale on characteristics of the therapists, such as level of empathy, is available, it

will be used.

### 237 **IPD integrity**

In order to check the integrity of the data received, a replication of the summary statistics and main analysis of each study will be attempted by two researchers, and if it fails, the authors will be asked for clarification. In addition, conventional MA with the aggregate data will be performed to replicate the existing findings, and the statistical package that we will use (multinma) accounts for differences by IPD availability status. More details are provided in the statistical analysis section.

### 243 Risk of bias and quality assessment

244 The risk of bias of the studies will be assessed using the Cochrane Risk of Bias Assessment 245 2.0(37), which assesses bias arising from the randomization process, bias due to deviations from the 246 intended interventions, bias due to missingness of outcome data, bias in the measurement of outcome, 247 and bias due to selective reporting of outcomes. Publication or small sample bias will be examined 248 through visual inspection of the funnel plots for each outcome. The overall quality of the evidence will 249 be assessed with the Grading of Recommendations Assessment, Development and Evaluation 250 (GRADE)—Guidelines (38), which, apart from the risk of bias, assesses inconsistency, indirectness, 251 imprecision and overall quality of the evidence. These assessments will be performed by two 252 independent researchers and disagreements will be resolved through discussion with a third more

253	senior	researcher. For the studies already assessed by Micklitz and colleagues (16), the domains of		
254	bias arising from missing data and selective outcome reporting will be revisited in case the IPD can			
255	elucidate previously unclear points. Publication bias will be assessed through a funnel plot and			
256	Egger's test.			
257	Cate	gorisation of interventions and control conditions		
258		Based on the work of Micklitz and colleagues, the interventions that have been tested so far		
259	can be	categorised into the following nodes:		
260	1.	Advocacy interventions: interventions based on the empowerment theory of Dutton (39) and		
261		the stages of change model (40), where facilitators use non-directive techniques such as		
262		motivational interviewing to guide the survivors to reach specialised services (also legal and		
263		financial ones), and to establish a safety plan		
264	2.	Integrative interventions: interventions combining the elements of the advocacy interventions		
265		with those of the psychological ones, including safety planning		
266	3.	Cognitive behavioural interventions: psychological interventions employing cognitive and		
267		behavioural techniques, such as cognitive restructuring		
268	4.	Third wave therapies: psychological interventions with more targeted cognitive approaches,		
269		such as mindfulness		
270	5.	Systemic interventions: family or couple based psychological interventions		
271	6.	Other psychological interventions: other psychological approaches tested by a small number		

272 of studies, such as interpersonal, humanistic or mindfulness/mediation based

273 The control conditions are expected to be categorised for the NMA as follows, unless different clusters

of control conditions with common elements appear in the final set of eligible studies:

275 1. Waiting list

276 2. No intervention

- 277 3. Information on services
- 278 4. Referral to services

- 279 5. Active psychiatric care
- 280 6. Contact
- 281 7. Community care
- 282 8. Support groups
- 283 9. Hotlines
- 284 However, small changes might be made depending on the elements included in the control conditions
- 285 of the included studies.

#### 286 **Outcomes and effect measures**

287 There is a vast array of psychosocial, risk lowering and safety-behaviour outcomes of interest

tested by the primary studies, which is not ideal to establish the effectiveness of interventions with

289 certainty, but it is the reality of the field (41). Psychosocial interventions use primarily psychological

techniques that target mental health symptoms (16). So, in our study, the primary outcomes are some

291 of the most commonly measured psychological distress symptoms of

- 292 1. depression
- 293 2. anxiety
- 294 3. PTSD

295 The secondary psychosocial outcomes are: suicidal ideation, substance use, perceived self-

efficacy, self-esteem, quality of life, social support, decisional conflict, empowerment, space for

297 action, all as scores in validated self- or clinician-rated scales, clinical interviews, or composites of

scales. The main timepoint is post-treatment, but all available follow-ups will be extracted, and if there

- is sufficient homogeneity in the timing of follow-ups, analyses will be conducted.
- 300 Additionally, the risk-lowering outcomes are: continuation of frequency/intensity of IPV, as a

301 whole (using the total scores of scales), and also the subtypes of psychological, physical, sexual abuse

- 302 and coercive control separately when available (as scores on subscales), which will all be
- 303 operationalised continuously as scores on validated (sub)scales. Safety-related behaviours will be

examined only if there is not too much heterogeneity in the definition and operationalisation of thisoutcome by the primary studies.

306 It is also interesting to investigate the effects of the interventions on service use, and 307 acceptability of the interventions. Service use will be operationalised as scores on checklists. 308 Satisfaction with the treatment will also be operationalised as scores on respective questionnaire items. 309 Acceptability of the interventions will be defined as the number of participants dropping out of the 310 intervention (not necessarily the whole study and assessments) (dichotomous outcome). The effect 311 size for all continuous outcomes will be Hedge's g, and for all dichotomous outcomes the odds ratios 312 will be calculated. Like for primary outcomes, the main timepoint of interest is post-treatment, but all 313 available follow-ups will be extracted, and if there is sufficient homogeneity in the timing of follow-314 ups, analyses will be conducted.

### 315 Statistical analysis-synthesis

316 Firstly, a conventional meta-analysis excluding studies comparing active psychosocial 317 interventions will be conducted to establish the overall efficacy of psychosocial interventions. 318 Secondly, an aggregate data network meta-analysis will be conducted to compare and rank the efficacy 319 of each psychosocial intervention; the active interventions that were tested as controls in the original 320 studies will be classified in the node of active interventions they share the same elements and 321 approaches with. Thirdly, an Individual Participant Data Meta-analysis will be conducted (excluding 322 the studies that compare two active psychosocial interventions) to establish the overall precise effects 323 and moderators of efficacy of psychosocial interventions as a whole. Given the high chance that 324 numerous potential moderators will be available, participant or intervention related, we will conduct 325 the analysis in two steps, as demonstrated by (42). Missing data will be multiply imputed for each 326 study using multiple imputation. If the regression coefficients are available in the publications of 327 studies that do not provide IPD, we will create pseudo-IPD for continuous outcomes, as described in 328 (43).

329 The same procedure will be repeated including all studies for the Individual Participant Data 330 Network meta-analysis. Additionally, in the first step we will select the variables that show a higher 331 interaction with the different nodes, by fitting a penalised linear regression model for continuous 332 outcomes and a penalised logistic regression for dichotomous outcomes. This will be done through the 333 lasso technique in STATA. In this step we will also test whether survivor and setting characteristics 334 (such as being separated or still living together with their partner, and clinical or community settings) 335 are effect modifiers or prognostic factors, and based on the results, the following stages of the analysis 336 will be divided into subgroups of studies that are similar in effect modifiers, so that the transitivity 337 assumption is met. In the second step, a one-stage IPDNMA will be conducted under a Bayesian 338 framework using the multinma package in R. The characteristics of the interventions, such as number 339 of sessions, format and mode of delivery will be tested as effect modifiers. We will also conduct a 340 multilevel network meta-regression (using multinma in R) to enable studies providing IPD to be 341 combined with those that do not, as demonstrated by (44). For the outcome of acceptability (defined as 342 dropout from the intervention) we will measure an absolute treatment effect, as many control 343 conditions are inactive, by modelling the probability of dropout through a generalised model of 344 binomial likelihood, as in (42). Heterogeneity will be assessed by comparing the fit of fixed and random effects models, reporting between-study variance,  $\tau^2$ , and explored through inspection of 345 346 regression coefficients and sub-group analyses. Inconsistency will be assessed by fitting a model that 347 relaxes the consistency assumption, and explored further using a node-splitting model. In all of the 348 aforementioned models where this is possible (aggregate data NMA, IPDMA, IPDNMA), if it is still 349 appropriate with the combination of elements/components the interventions consist of, we will explore 350 fitting IPD component NMA models (45,46,47). A sensitivity analysis excluding studies with high risk 351 of bias will be conducted separately for each bias domain. The rankings of the interventions and the 352 Surface Under the Cumulative Ranking (SUCRA) scores will be calculated to summarise the results of 353 the IPDNMA.

The results of all analyses will be compared to further investigate the precision of the estimates.

# 356 **Discussion**

We plan to conduct an IPDNMA to estimate precisely the effects of psychosocial interventions on the mental health of IPV survivors, to compare the interventions, and to examine potential moderating effects of the characteristics of the participants and the interventions. We intend to fulfil this aim by establishing a collaboration with the authors of the RCTs and thus obtaining the datasets of the studies and combining them.

### 362 Strengths and limitations

363 This methodology is considered a gold standard in evidence synthesis (27) and it is novel in 364 the field of IPV. The synthesis approach allows research findings to be integrated to increase precision 365 (26), whilst thoroughly investigating factors affecting the effects of the interventions on the outcomes 366 with advanced statistical methods. These factors will pertain to individuals, interventions and contexts, 367 and possibly their interaction, to address heterogeneity as fully as possible. The certainty of the 368 evidence will also be assessed under the GRADE method (38). 369 However, there are admittedly limitations to our approach. We will be limited by the data 370 measured in the included studies, and statistical power is bound to vary across outcomes. In addition,

harmonising the outcomes across studies that have measured them in different ways means that somenuancing might be missed, but we plan to address this by sensitivity analyses. Another common issue

of IPDMAs is that the IPD are often impossible to obtain (48). We plan to deal with this issue by

attempting to contact the researchers through different channels and by using pseudo-IPD (43). Efforts

will be made to reduce publication bias by expanding the literature search of Micklitz and colleagues,

and searching trial registries and grey literature.

### 377 **Relevance**

The field of IPV is highly heterogeneous, and matching individuals and contexts withinterventions is crucial (17). This has not been done yet with quantitative methods that limit personal

380	biases and offer precise estimates of the impact of each of the many factors intertwined in the
381	provision of psychosocial support of IPV survivors. Pinpointing impactful factors and comparing the
382	existing interventions can contribute to more efficient decision making both for practice and policy.
383	S1 Table. Eligibility criteria by PICO
384	Funding statement: Christina Palantza is in receipt of an annual stipend from the University of
385	Bristol from 2023 to 2027. This is the only funding source of this review. The funder had no role in
386	the development of this protocol.
387	Author contributions: Christina Palantza conceptualised the main aims and methods of the review,
388	drafted the protocol. Karen Morgan and Gene Feder oversaw the development of the protocol and
389	provided expert advice on conceptual aspects. Nicky Welton oversaw the development of the protocol
390	and provided expert advice on methodological and statistical aspects. Lasse Sander and Hannah
391	Micklitz conducted the systematic review and meta-analysis that is to be updated and extended by this
392	review, reviewed the protocol and provided the materials of their review.
393	Financial competing interest: None apart from CP's stipend.
394	Non-Financial competing interest: None
394 395	Non-Financial competing interest: None Patient and Public Involvement: A Patient and Public Involvement group of survivors of intimate
394 395 396	Non-Financial competing interest: None Patient and Public Involvement: A Patient and Public Involvement group of survivors of intimate partner violence from the UK was consulted and provided input on conceptual aspects.
394 395 396 397	<ul> <li>Non-Financial competing interest: None</li> <li>Patient and Public Involvement: A Patient and Public Involvement group of survivors of intimate partner violence from the UK was consulted and provided input on conceptual aspects.</li> <li>Transparency Declaration: Christina Palantza affirms that the manuscript is an honest, accurate, and</li> </ul>
394 395 396 397 398	Non-Financial competing interest: None Patient and Public Involvement: A Patient and Public Involvement group of survivors of intimate partner violence from the UK was consulted and provided input on conceptual aspects. Transparency Declaration: Christina Palantza affirms that the manuscript is an honest, accurate, and transparent account of the study being outlined; no important aspects of the study have been omitted.
394 395 396 397 398 399	Non-Financial competing interest: NonePatient and Public Involvement: A Patient and Public Involvement group of survivors of intimate partner violence from the UK was consulted and provided input on conceptual aspects.Transparency Declaration: Christina Palantza affirms that the manuscript is an honest, accurate, and transparent account of the study being outlined; no important aspects of the study have been omitted.Data Availability Statement: Data availability is not applicable to this article as it is a protocol
<ul> <li>394</li> <li>395</li> <li>396</li> <li>397</li> <li>398</li> <li>399</li> <li>400</li> </ul>	Non-Financial competing interest: NonePatient and Public Involvement: A Patient and Public Involvement group of survivors of intimate partner violence from the UK was consulted and provided input on conceptual aspects.Transparency Declaration: Christina Palantza affirms that the manuscript is an honest, accurate, and transparent account of the study being outlined; no important aspects of the study have been omitted.Data Availability Statement: Data availability is not applicable to this article as it is a protocol merely outlining research that has not been conducted yet. Upon completion of the study, it will still
<ul> <li>394</li> <li>395</li> <li>396</li> <li>397</li> <li>398</li> <li>399</li> <li>400</li> <li>401</li> </ul>	Non-Financial competing interest: None         Patient and Public Involvement: A Patient and Public Involvement group of survivors of intimate         partner violence from the UK was consulted and provided input on conceptual aspects.         Transparency Declaration: Christina Palantza affirms that the manuscript is an honest, accurate, and         transparent account of the study being outlined; no important aspects of the study have been omitted.         Data Availability Statement: Data availability is not applicable to this article as it is a protocol         merely outlining research that has not been conducted yet. Upon completion of the study, it will still         not be possible to make the data publicly available, as it belongs to the researchers that conducted the
<ul> <li>394</li> <li>395</li> <li>396</li> <li>397</li> <li>398</li> <li>399</li> <li>400</li> <li>401</li> <li>402</li> </ul>	Non-Financial competing interest: None Patient and Public Involvement: A Patient and Public Involvement group of survivors of intimate partner violence from the UK was consulted and provided input on conceptual aspects. Transparency Declaration: Christina Palantza affirms that the manuscript is an honest, accurate, and transparent account of the study being outlined; no important aspects of the study have been omitted. Data Availability Statement: Data availability is not applicable to this article as it is a protocol merely outlining research that has not been conducted yet. Upon completion of the study, it will still not be possible to make the data publicly available, as it belongs to the researchers that conducted the eligible studies; they are to share them with us only for the purposes of this study.
<ul> <li>394</li> <li>395</li> <li>396</li> <li>397</li> <li>398</li> <li>399</li> <li>400</li> <li>401</li> <li>402</li> <li>403</li> </ul>	<ul> <li>Non-Financial competing interest: None</li> <li>Patient and Public Involvement: A Patient and Public Involvement group of survivors of intimate partner violence from the UK was consulted and provided input on conceptual aspects.</li> <li>Transparency Declaration: Christina Palantza affirms that the manuscript is an honest, accurate, and transparent account of the study being outlined; no important aspects of the study have been omitted.</li> <li>Data Availability Statement: Data availability is not applicable to this article as it is a protocol merely outlining research that has not been conducted yet. Upon completion of the study, it will still not be possible to make the data publicly available, as it belongs to the researchers that conducted the eligible studies; they are to share them with us only for the purposes of this study.</li> </ul>

# 404 **References**

405	1.	Mitchell C, Anglin D. Intimate partner violence : a health-based perspective. Oxford ; New
406		York: Oxford University Press; 2009.

- 407 2. Jonas S, Khalifeh H, Bebbington PE, McManus S, Brugha T, Meltzer H, et al. Gender
- 408 differences in intimate partner violence and psychiatric disorders in England: results from the
- 4092007 adult psychiatric morbidity survey. Epidemiology and Psychiatric Sciences. 2013 Jun
- 410 10;23(2):189–99.
- 411 3. Trevillion K, Oram S, Feder G, Howard LM. Experiences of Domestic Violence and
- 412 Mental Disorders: A Systematic Review and Meta-Analysis. van Os J, editor. PLoS
- 413 ONE [Internet]. 2012 Dec 26;7(12):e51740. Available from: https://research-
- 414 information.bristol.ac.uk/files/84447061/journal.pone.0051740.pdf
- 415 4. Fogarty A, Brown SJ, Gartland D, Mensah F, FitzPatrick KM, Giallo R. Mental health
- 416 trajectories of women experiencing differing patterns of intimate partner violence across the
- 417 first 10 years of motherhood. Psychiatry Research [Internet]. 2023 Jul 1 [cited 2023 Jun
- 418 27];325:115261. Available from:
- 419 <u>https://www.sciencedirect.com/science/article/pii/S0165178123002111</u>
- 420 5. WHO | Understanding and addressing violence against women. Whoint [Internet].
- 421 2014 Nov 28; Available from:
- 422 https://www.who.int/reproductivehealth/topics/violence/vaw\_series/en/
- 423 6. Bogat GA, Levendosky AA, Cochran K. Developmental Consequences of Intimate
  424 Partner Violence on Children. Annual Review of Clinical Psychology. 2023 Feb
- 425 15;19(1).
- 426
  426
  427
  427
  428
  427
  428
  429
  429
  429
  420
  420
  420
  420
  420
  421
  421
  421
  421
  422
  421
  422
  423
  423
  424
  424
  425
  425
  426
  426
  427
  427
  428
  428
  429
  429
  429
  420
  420
  420
  420
  420
  421
  421
  421
  421
  421
  422
  421
  422
  421
  422
  421
  422
  421
  422
  421
  421
  421
  422
  421
  422
  421
  422
  421
  421
  421
  421
  421
  421
  421
  421
  421
  422
  421
  422
  422
  422
  423
  424
  424
  424
  425
  424
  425
  425
  425
  425
  426
  426
  426
  427
  426
  427
  427
  428
  428
  428
  428
  428
  428
  429
  429
  429
  429
  429
  429
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
- 427 nearm-related behaviors of women. A systematic review of the merature. Trau
- 428 Violence, & Abuse. 2021 Feb 5;23(4):1157–72.

429	8.	Ulloa EC, Hammett JF. The Effect of Gender and Perpetrator-Victim Role on Mental
430		Health Outcomes and Risk Behaviors Associated With Intimate Partner Violence.
431		Journal of Interpersonal Violence. 2014 Dec 18;31(7):1184–207.
432	9.	Kim B, Royle M. Domestic Violence in the Context of the COVID-19 Pandemic: A
433		Synthesis of Systematic Reviews. Trauma, Violence, & Abuse. 2023 Feb
434		27;152483802311555
435	10.	Carlson C, Namy S, Norcini Pala A, Wainberg ML, Michau L, Nakuti J, et al.
436		Violence against children and intimate partner violence against women: overlap and
437		common contributing factors among caregiver-adolescent dyads. BMC Public Health.
438		2020 Jan 29;20(1).
439	11.	Campbell L, Jin K, Uhlich M, Francis JM, Mark K, Miall N, et al. Intimate Partner
440		Violence During COVID-19 Restrictions: A Study of 30 Countries From the I-
441		SHARE Consortium. 2023 Jan 26;088626052211418-088626052211418.
442	12.	Whiting K. The cost-of-living crisis is having a global impact - here's what countries
443		are doing to help [Internet]. World Economic Forum. 2022. Available from:
444		https://www.weforum.org/agenda/2022/09/cost-of-living-crisis-global-impact/
445	13.	Cost of Living and the impact on survivors of domestic abuse [Internet]. Available
446		from: https://www.womensaid.org.uk/wp-content/uploads/2023/01/Cost-of-Living-
447		Crisis-Impact-on-Survivors-of-DA.docx.pdf
448	14.	Oram S, Fisher HL, Minnis H, Seedat S, Walby S, Hegarty K, et al. The Lancet
449		Psychiatry Commission on intimate partner violence and mental health: advancing
450		mental health services, research, and policy. The Lancet Psychiatry [Internet]. 2022
451		Jun 1 [cited 2022 May 16];9(6):487–524. Available from:
452		https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(22)00008-
453		<u>6/fulltext?fbclid=IwAR2DG_eBCn9sS-</u>
454		2mkRayn0rLX3IUdHSLO2iizCvX1muEhhfTQX1mqZ74dEo

455	15.	Karakurt G, Koç E, Katta P, Jones N, Bolen SD. Treatments for Female Victims of
456		Intimate Partner Violence: Systematic Review and Meta-Analysis. Frontiers in
457		Psychology. 2022 Feb 4;13(1).
458	16.	Micklitz HM, Glass CM, Bengel J, Sander LB. Efficacy of Psychosocial Interventions
459		for Survivors of Intimate Partner Violence: A Systematic Review and Meta-Analysis.
460		Trauma, Violence, & Abuse. 2023 May 6;152483802311694.
461	17.	Rivas C, Vigurs C, Cameron J, Yeo L. A realist review of which advocacy
462		interventions work for which abused women under what circumstances. Cochrane
463		Database of Systematic Reviews. 2019 Jun 29;
464	18.	Hameed M, O'Doherty L, Gilchrist G, Tirado-Muñoz J, Taft A, Chondros P, et al.
465		Psychological therapies for women who experience intimate partner violence: a
466		Cochrane Review. BJPsych Advances. 2021 Oct 25;27(6):356-6.
467	19.	Paphitis SA, Bentley A, Asher L, Osrin D, Oram S. Improving the mental health of
468		women intimate partner violence survivors: Findings from a realist review of
469		psychosocial interventions. Munro-Kramer ML, editor. PLOS ONE. 2022 Mar
470		17;17(3):e0264845.
471	20.	Austin AE, Shanahan ME, Barrios YV, Macy RJ. A Systematic Review of
472		Interventions for Women Parenting in the Context of Intimate Partner Violence.
473		Trauma, Violence, & Abuse. 2017 Jul 21;20(4):498–519.
474	21.	Chu YC, Wang HH, Chou FH, Hsu Y, Liao KL. Outcomes of trauma informed care
475		on the psychological health of women experiencing intimate partner violence: A
476		systematic review and meta analysis. Journal of Psychiatric and Mental Health
477		Nursing. 2023 Sep 12;
478	22.	Vicente Escudero JL & Sánchez Navarro B. Meta-Analysis of Webbased Treatments
479		for PTSD in Women Exposed to Intimate Partner Violence and Sexual Abuse.
480		International Journal of Psychology & Psychological Therapy. 2023 Mar 1;23(1): 93-
481		105.

482	23. Linde DS.	Bakiewicz A.	Normann AK	. Hansen NB.	Lundh A.	Rasch V	V. Intimate

- 483 Partner Violence and Electronic Health Interventions: Systematic Review and Meta-
- 484 Analysis of Randomized Trials. Journal of Medical Internet Research [Internet]. 2020
- 485 Dec 11 [cited 2021 Apr 15];22(12):e22361. Available from:
- 486 <u>https://www.jmir.org/2020/12/e22361/</u>
- 487 24. Tirado-Muñoz J, Gilchrist G, Farré M, Hegarty K, Torrens M. The efficacy of
- 488 cognitive behavioural therapy and advocacy interventions for women who have
- 489 experienced intimate partner violence: A systematic review and meta-analysis. Annals
- 490 of Medicine. 2014 Sep 11;46(8):567–86.
- 491 25. Riley RD, Tierney JF, Stewart LA. Individual participant data meta-analysis : a
- 492 handbook for healthcare research. Hoboken, Nj: Wiley; 2021.
- 49326. Cooper H, Patall EA. The relative benefits of meta-analysis conducted with individual
- 494 participant data versus aggregated data. Psychological Methods. 2009;14(2):165–76.
- 495 27. Abo-Zaid G, Sauerbrei W, Riley RD. Individual participant data meta-analysis of prognostic
- 496 factor studies: state of the art? BMC Medical Research Methodology. 2012 Apr 24;12(1).
- 497 28. Broeze KA, Opmeer BC, van der Veen F, Bossuyt PM, Bhattacharya S, Mol BWJ. Individual
- 498 patient data meta-analysis: a promising approach for evidence synthesis in reproductive
- 499 medicine. Human Reproduction Update. 2010 Sep 6;16(6):561–7.
- 50029. Craven LC, Fields AM, Carlson RG, Combs EM, Howe ES. Counseling interventions
- 501 for victims of intimate partner violence: A systematic review. 2023 May 13;
- 50230. 5 ways to strengthen our health systems for the future [Internet]. World Economic
- 503 Forum. Available from: <u>https://www.weforum.org/agenda/2022/01/5-ways-to-</u>
- 504 strengthen-our-health-systems-for-the-future-healthcare/
- 505
- 506 31. Dias S, Ades AE, Welton NJ, Jansen JP, Sutton AJ. Network meta-analysis for
  507 comparative effectiveness research. Hoboken, New Jersey: John Wiley & Sons Ltd;
  508 2018.

509	32.	Chaimani A, Caldwell DM, Li T, Higgins JPT, Salanti G. Chapter 11: Undertaking
510		network meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T,
511		Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of
512		Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from
513		www.training.cochrane.org/handbook.
514	33.	Kanters S, Karim ME, Thorlund K, Anis A, Bansback N. When does the use of
515		individual patient data in network meta-analysis make a difference? A simulation
516		study. BMC Medical Research Methodology. 2021 Jan 13;21(1).
517	34.	Riley RD, Dias S, Donegan S, Tierney JF, Stewart LA, Efthimiou O, et al. Using
518		individual participant data to improve network meta-analysis projects. BMJ Evidence-
519		Based Medicine [Internet]. 2023 Jun 1 [cited 2023 Jul 17];28(3):197-203. Available
520		from: https://ebm.bmj.com/content/28/3/197
521	35.	Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred
522		Reporting Items for Systematic Review and meta-analysis Protocols (PRISMA-P)
523		2015 Statement. Systematic Reviews [Internet]. 2015 Jan 1;4(1):1–9. Available from:
524		https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/2046-4053-4-1
525	36.	Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a Web and Mobile
526		App for Systematic Reviews. Systematic Reviews [Internet]. 2016 Dec;5(1).
527		Available from:
528		https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-016-
529		0384-4
530	37.	Higgins, JPT, Thomas, J, Chandler, J, Cumpston, M, Li, T, Page, M, & Welch, V.
531		Cochrane handbook for systematic reviews of interventions version 6.3 (updated
532		February 2022) John Wiley. <u>www.training.cochrane.org/handbook</u>
533	38.	How to GRADE the quality of the evidence [Ryan &Hill]. Available from:
534		https://colorectal.cochrane.org/sites/colorectal.cochrane.org/files/public/uploads/how_
535		to grade.pdf

536	39.	Mary Ann Dutton. Empowering and Healing the Battered Woman. Springer
537		Publishing Company; 2000.
538	40.	Prochaska JO, DiClemente CC. Transtheoretical therapy: Toward a more integrative
539		model of change. Psychotherapy: Theory, Research & Practice [Internet].
540		1982;19(3):276–88. Available from: <u>https://psycnet.apa.org/record/1984-26566-001</u>
541	41.	Sprague S, McKay P, Madden K, Scott T, Tikasz D, Slobogean GP, et al. Outcome
542		Measures for Evaluating Intimate Partner Violence Programs Within Clinical Settings:
543		A Systematic Review of the Literature. Trauma, Violence, & Abuse. 2016 Apr
544		5;18(5):508–22.
545	42.	Furukawa TA, Karyotaki E, Suganuma A, Pompoli A, Ostinelli EG, Cipriani A, et al.
546		Dismantling, personalising and optimising internet cognitive-behavioural therapy for
547		depression: a study protocol for individual participant data component network meta-
548		analysis. BMJ Open. 2018 Nov;8(11):e026137.
549	43.	Papadimitropoulou K, Stijnen T, Riley RD, Dekkers OM, Cessie S. Meta analysis of
550		continuous outcomes: Using pseudo IPD created from aggregate data to adjust for
551		baseline imbalance and assess treatment $\Box$ by $\Box$ baseline modification. Research
552		Synthesis Methods. 2020 Jul 25;
553	44.	Phillippo DM, Dias S, Ades AE, Belger M, Brnabic A, Schacht A, et al. Multilevel network
554		meta regression for population adjusted treatment comparisons. Journal of the Royal
555		Statistical Society: Series A (Statistics in Society). 2020 Jun;183(3):1189–210.
556	45.	Welton NJ, Caldwell DM, Adamopoulos E, Vedhara K. Mixed Treatment Comparison Meta-
557		Analysis of Complex Interventions: Psychological Interventions in Coronary Heart Disease.
558		American Journal of Epidemiology. 2009 Mar 3;169(9):1158-65.
559	46.	Caldwell DM, Welton NJ. Approaches for synthesising complex mental health
560		interventions in meta-analysis. Evidence Based Mental Health. 2016 Jan 20;19(1):16-
561		21.

562	47. Petropoulou M, Efthimiou O, Rücker G, Schwarzer G, Furukawa TA, Pompoli A, et al. A
563	review of methods for addressing components of interventions in meta-analysis. Mathes T,
564	editor. PLOS ONE. 2021 Feb 8;16(2):e0246631.
565	48. Wang H, Chen Y, Lin Y, Abesig J, Wu IX, Tam W. The methodological quality of individual
566	participant data meta-analysis on intervention effects: systematic review. BMJ. 2021 Apr
567	19;n736.
568	
569	
570	
F71	
5/1	
572	
573	
574	
575	
576	
577	
578	
579	
580	
504	
581	
582	
583	
584	